Responses
Oral Presentations
Immunogenicity of biologics; myth or reality?
OP0203 Impact of adalimumab serum concentration on efficacy and association between ANTI-DRUG antibodies and serum concentration: 24 week results from a phase III study comparing SB5 (an adalimumab biosimilar) with reference adalimumab in patients with rheumatoid arthritis
Compose a Response to This Article
Other responses
No responses have been published for this article.